Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity

Oncogene

Volumn 28, Issue 11, 2009, Pages 1477-1484

  Zubia, A ^a,b   Ropero, S ^c,d,e   Otaegui, D ^a   Ballestar, E ^c,d   Fraga, M F ^c   Boix Chornet, M ^c   Berdasco, M ^c,d   Martinez, A ^f   Coll Mulet, L ^g   Gil, J ^g   Cossio F P ^a   Esteller, M ^c,d,h,i  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Ikerchem Ltd   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^e UNIVERSITY OF ALCALÁ   (Spain)

^f INSTITUTO CAJAL   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

ⁱ HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Angiogenesis; Cancer; Computational modeling; Epigenetics; Histone deacetylase inhibitors; Histones

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; PYRROLE DERIVATIVE;

ACETYLATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICE; MODELS, MOLECULAR; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 62649091666     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.501     Document Type: Article

References (19)

1. Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE. (2007). Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem 7: 576-592.
2. Chiorazzi N, Rai KR, Ferrarini M. (2005). Chronic lymphocytic leukemia. N Engl J Med 352: 804-815.
3. Esteller M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298.
4. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
5. Folkman J. (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
6. Jenuwein T, Allis CD. (2001). Translating the histone code. Science 293: 1074-1080.
7. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443.
8. Kouzarides T. (2007). Chromatin modifications and their function. Cell 128: 693-705.
9. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 46: 3-26.
10. Maier T, Bar T, Beckers T, Zimmermann A, Dullweber F, Gekeler V. (2006). Sulfonylpyrroles as histone deacetylase inhibitors. WO/2006/105979.
11. Marks PA. (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-1356.
12. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P et al. (2001). 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J Med Chem 44: 2069-2072.
13. Richardson B. (2007). Primer: epigenetics of autoimmunity. Nat Clin Pract Rheumatol 3: 521-527.
14. Sadri-Vakili G, Cha JH. (2006). Mechanisms of disease: histone modifications in Huntington's disease. Nat Clin Pract Neurol 2: 330-338.
15. Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ et al. (2004). Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12: 1325-1334.
16. Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D et al. (2004). Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101: 15064-15069.
17. Villar-Garea A, Esteller M. (2004). Histone deacetylase inhibitors: understanding a new wave of anticancer reagents. Int J Cancer 112: 171-178.
18. Vivanco S, Lecea B, Arrieta A. (2000). Origins of the loss of concertedness in pericyclic reactions: theoretical prediction and direct observation of stepwise mechanisms in [3+2] thermal cycloadditions. J Am Chem Soc 122: 6078-6092.
19. Wang D-F, Wiest O, Helquist P, Lan-Hargest H-Y, Wiech NL. (2004). On the function of the 14Å long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem 47: 3409-3417.